Compare Deckers Outdoor Corp (DECK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs TG Therapeutics Inc — how do they compare? Deckers Outdoor Corp trades at $94.12 (market cap $13.27B), while TG Therapeutics Inc trades at $49.65 (market cap $7.53B). The key difference: Deckers Outdoor Corp is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals.
| DECK | TGTX | |
|---|---|---|
Market Cap | $13.27B | $7.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $123.91 | $59.06 |
52-Week Low | $79.54 | $26.94 |
Enterprise Value | $12.14B | $7.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers Outdoor (DECK) trades at $97.46, down 0.42% with bearish technical signals but strong fundamentals. The company reported consistent earnings beats with Q1 2026 EPS of $0.96 beating expectations of $0.81. Revenue grew to $4.99 billion in 2025 with impressive 18.36% net margin and 42.56% ROE. Analyst consensus remains positive with 45% buy ratings and $122.40 price target, though recent guidance concerns caused a 6% selloff.
DECK offers compelling value with a 13.86 P/E ratio below industry averages, supported by HOKA and UGG brand strength. Key risks include tariff headwinds, brand concentration, and execution challenges. The stock presents a growth opportunity at current levels but faces near-term volatility from macroeconomic pressures and competitive dynamics in the apparel sector.
TG Therapeutics (TGTX) trades at $49.76, up 0.42% in the last session, with a bearish technical signal from moving averages. Recent earnings missed estimates, but revenue growth is strong, driven by BRIUMVI sales, with 2026 guidance raised to $950 million. The stock faces near-term pressure from earnings underperformance and a legal investigation into potential fiduciary breaches.
The outlook is mixed: strong revenue momentum and a high analyst buy rating (84.62%) support upside to the $63.75 consensus target, but risks include earnings volatility, high valuation multiples, and legal overhangs. Investors should weigh robust growth prospects against execution and sentiment challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
